TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06766721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (USG)
Description: The intervention involves the use of a portable ultrasound (USG) device to assess costochondral joint separation in patients with blunt thoracic trauma. The ultrasound examination will focus on detecting disruptions in the connection between the ribs and cartilage, providing a non-invasive, radiation-free diagnostic method. A 12-MHz linear transducer will be used to scan the rib area for fractures or separations. The findings will be compared to those of computed tomography (CT), considered the gold standard. This intervention is designed to evaluate the accuracy, sensitivity, and specificity of ultrasound as a diagnostic tool in this context.
Study: NCT06766032

Intervention type: DEVICE
Intervention: CELL-Saver
Description: The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.

Intervention type: DEVICE
Intervention: SAME
Description: The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
Study: NCT06766227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEndSmokin App
Description: Mobile Health App that includes educational material and psychological programs based on CBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Session
Description: It will include lectures and distribution of educational material about smoking health risks and strategies to quit.
Study: NCT06765486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb resistance training
Description: Exercise intervention with leg extensions on the dominant quadriceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb resistance training
Description: Exercise intervention with brachial biceps curl on the dominant brachial biceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
Study: NCT06766851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: TMJ Arthrocentesis
Description: Temporomandibular joint arthrocentesis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: TMJ Arthrocentesis
Description: Temporomandibular joint arthrocentesis
Study: NCT06769295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
Study: NCT06769464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: odor
Description: present odor
Study: NCT06768476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART123 Cells
Description: 1.3x10\^8 CART123 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART123 Cells
Description: 1.3x10\^8 CART123 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 MG Oral Tablet
Description: Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 MG
Description: Twice Daily
Study: NCT06769776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Drain i.e. Omission of abdominal drain placement
Description: Omission of abdominal drain placement in intervention arm. The No-drain arm will be compared to drain arm
Study: NCT06769867

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PS-3D-DSA
Description: undergo a PS-3D-DSA scan

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: classic 3D-DSA
Description: undergo a classic 3D-DSA scan
Study: NCT06768073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham (No Treatment)
Description: The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
Study: NCT06768944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin 25 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin 1 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin 1 mg
Description: The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone 750 mg
Description: metyrapone 750mg capsules, which will be administered in 2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone 750 mg
Description: metyrapone 750mg capsules, which will be administered in 2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: inactive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo
Study: NCT06767943

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead electrocardiography
Description: All patients were admitted to the intermediate care unit for the 1st 24-h PO for follow-up for the possibility of developing acute myocardial infarction (AMI), which was diagnosed according to the 2017 ESC Guidelines; by 12- lead electrocardiography
Study: NCT06768281

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Headache Impact Test-6 (HIT-6)
Description: Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Headache Impact Test-6 (HIT-6)
Description: Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Score (VAS)
Description: Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Score (VAS)
Description: Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masseter muscle injection
Description: 1 ml of insulin needle with a 27-gauge ½ inch 13 mm needle tip will be injected into up to 4 trigger points in the taut bands that cause the most pain in the masseter muscle. Injections were done at most 3 times. As the control group, the first group was injected with isotonic saline; the second group was injected with 2% lidocaine without vasoconstrictor; the third group with ozone gas; and the fourth group with ozonated isotonic saline.
Study: NCT06767748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: GZR4 s.c., once-weekly，treat-to-target dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: insulin degludec s.c.,once-daily，treat-to-target dose
Study: NCT06768268

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer
Description: The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer
Description: The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer
Description: The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer
Description: The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer
Description: The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: Adding Mannitol into Voluven and used as solvent of ICG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: Adding Mannitol into Voluven and used as solvent of ICG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: Adding Mannitol into Voluven and used as solvent of ICG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: Adding Mannitol into Voluven and used as solvent of ICG
Study: NCT06769672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active tDCS with dual-task training
Description: participants receive three 20-minute active tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS with dual-task training
Description: participants receive three 20-minute sham tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
Study: NCT06769230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strengthening exercise
Description: The participants will perform warm-up exercises including Cat and Camel, spinal movement (spinal flexion and extension cycles), and stretching exercises for the calf, hamstrings, quadriceps and lower back for about 5 minutes. After that, the women will be asked to perform core stability exercises including abdominal hollowing, bilateral knee raise, supine extension Bridge, straight leg rise from prone and alternate arm and leg raise from quadruped. Each exercise will be repeated for 10 times with 7-8 seconds hold and will be increased by four repetitions each week throughout the interventions. During each repetition for every exercise, the patient will be asked to contract her abdominal muscles and maintain this contraction while maintaining her normal breathing pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core strengthening exercise
Description: The participants will perform warm-up exercises including Cat and Camel, spinal movement (spinal flexion and extension cycles), and stretching exercises for the calf, hamstrings, quadriceps and lower back for about 5 minutes. After that, the women will be asked to perform core stability exercises including abdominal hollowing, bilateral knee raise, supine extension Bridge, straight leg rise from prone and alternate arm and leg raise from quadruped. Each exercise will be repeated for 10 times with 7-8 seconds hold and will be increased by four repetitions each week throughout the interventions. During each repetition for every exercise, the patient will be asked to contract her abdominal muscles and maintain this contraction while maintaining her normal breathing pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory motor training
Description: The participants will perform warm-up exercises including neck rotations, arm circles, ankle rotations, trunk rotations, trunk bending and extending for 5-10 mins. After warm up the women performs Bosu ball exercises including Bosu ball one Leg Bridge, Bosu Crunch, Bosu Sit ups, Bosu compressions, Bosu side crunch and Bosu bodyweight squat . Each exercise will be repeated for 6 repetitions in each set. At least 3 sets of each exercise are performed per session. Each exercise will be increased by five repetitions each week throughout the interventions.The total duration of each session is 45 minutes.
Study: NCT06769555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-336 BCMA/CD3 bispecific antibody
Description: Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
Study: NCT06768034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Patients being referred to an internist or cardiologist after myocardial injury after noncardiac surgery
Study: NCT06769334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLAY Program
Description: The PLAY Program is a web-based program created for caregivers of childhood cancer survivors. The program consists of seven modules with the following topics: 1) Introduction to the program 2) Self-Care 3) Relationships 4) Getting Ready for School 5) Talking, Reading, and Counting together 6) Social and Emotional Development 7) Review Module. The program is meant to be completed over approximately three months, and caregivers in the program will meet with a coach on a weekly or bi-weekly basis to discuss what they learned in the modules and how to practice it in their daily lives.
Study: NCT06767670

Intervention type: OTHER
Intervention: stainless steel crown
Description: familiar method of managing multi-surface carious lesions in primary teeth

Intervention type: OTHER
Intervention: bioflex crown
Description: aesthetic preformed pediatric crowns that offer the properties of both stainless steel and zirconia crowns
Study: NCT06769009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention measures on iodine, iodine deficiency and iodine intake
Description: The intervention consist of an educational intervention which will educate the young women on the importance of iodine, the consequences of iodine deficiency, dietary iodine sources and the iodine in pregnancy. The educational intervention consist of four intervention components: an iodine feedback tool, and educational iodine conversation with a healthcare professional, an iodine factsheet and an iodine video. The healthcare professionals who carry out the educational conversation will receive a specially designed training program.
Study: NCT06767878

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PORTiSOFIE
Description: This treatment is based on the Clark and Wells model of social phobia, and it is constituted by 9 modules:~1. Introduction of the program and overview of social anxiety disorder and symptoms~2. Negative automatic thoughts~3. Challenging negative automatic thoughts~4. Behavioral experiments~5. Exposure~6. Exposure and self-focus attention~7. Exposure and get closer to fears~8. Social skill training~9. Maintenance plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PORTiSOFIE
Description: This treatment is based on the Clark and Wells model of social phobia, and it is constituted by 9 modules:~1. Introduction of the program and overview of social anxiety disorder and symptoms~2. Negative automatic thoughts~3. Challenging negative automatic thoughts~4. Behavioral experiments~5. Exposure~6. Exposure and self-focus attention~7. Exposure and get closer to fears~8. Social skill training~9. Maintenance plan
Study: NCT06769061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will receive 6 weeks of electroacupuncture, 2 sessions per week, 30 min per session Stainless steel, single-use, sterile, and disposable needles will be used. We will use the bilateral acupoints LI4 (He-Gu), TE5 (Wai-Guan), LI11 (Qu-Chi), and LU5 (Chi-Ze) for upper limbs. For lower limb numbness, we will use the bilateral acupoints of LV3 (Tai-Chong), ST41 (Jie-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan) for the numbness of back of feet, or the bilateral acupoints of KI1 (Yong-Quan), KI3 (Tai-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan). After skin disinfection, sterile adhesive pads will be placed on bilateral LI4 (Hegu), TE5 (Waiguan), LI11 (Quchi), and LU5 (Chize). Following each needle insertion, acupuncturists will perform equal manipulations of twirling, lifting, and thrusting on the needle by acupuncturists to achieve the de qi sensation. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be electrically stimulated for 30 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Patients will receive 6 weeks of sham acupuncture, 2 sessions per week, 30 min per session. The Streitberger sham acupuncture needle designed specifically for sham acupuncture trials will be used. Patients will feel the needle on the skin, but the needle actually will not puncture the skin. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be connected to the electrical stimulation device KWD-808I MULTI-PURPOSE Health device (Great Wall Company), but not stimulated. The needle will remain for 30 minutes. without stimulating the acupoints. The sham acupuncture will be used within the trocar. The trocar will be fixed by a base on the skin with sticker. The trocar-base-sticker will be used for both acupuncture group and sham acupuncture control group, so they are exactly the same in appearance. Patients cannot see if there is acupuncture or sham acupuncture within the trocar.
Study: NCT06769893

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RCCB6 PET/CT Scan
Description: The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations.~Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL.
Study: NCT06768177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: 3 ML OF PRP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprostadil 20 micrograms
Description: 1 ML
Study: NCT06764966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 mg
Description: Atorvastatin 20 mg Once Daily with previously prescribed Non Selective Beta-Blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
Study: NCT06766019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
Description: 1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles
Study: NCT06769958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology application